본문 바로가기
KERD
논문KCI 등재

대한갑상선학회 갑상선분화암 진료권고안; Part III. 진행성 갑상선분화암의 치료 - 제4장 진행성 방사성요오드 불응성 갑상선분화암의 전신항암치료 2024

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 4. Systemic Therapy for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer 2024

김선욱|박영주|이은경|나동규|정윤재|송영신|김원구|임동준|강호철|신동엽
대한갑상선학회 (Korean Thyroid Association)|2024.05|International Journal of Thyroidology|제17권 제1호|pp. 168-181

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

Guideline방사성요오드Radioactive iodineTyrosine kinase inhibitorSystemic therapy진료권고안대한갑상선학회Korean Thyroid Association불응성 갑상선암전신항암치료키나아제 억제제국소 치료Refractory thyroid cancerLocal therapy
주제분류의학일반

초록

The primary treatment for differentiated thyroid cancer (DTC) with distant metastasis is high-dose radioactive iodine (RAI) therapy, which can have various effects depending on the iodine uptake of thyroid cancer cells. The iodine uptake of metastatic lesions decreases over time, and approximately 40-70% of patients eventually develop RAI refractory disease. Although the prognosis of patients with RAI refractory DTC is very poor, clinical outcomes vary depending on the location and progression of metastatic lesions. Therefore, it is crucial to determine which patients should receive active systemic therapy with tyrosine kinase inhibitor (TKI) and how to apply local treatment before or during systemic therapy. This guideline covers the definition, treatment principles, systemic anticancer agents, and complications of progressive RAI-refractory DTC. RAI refractory DTC is defined as (1) the absence of RAI uptake on whole body scan, (2) presence of RAI uptake in some lesions but not in others, or (3) disease progression despite RAI uptake. Treatment options for RAI refractory DTC include surgery, external beam radiation therapy, locoregional therapies such as high-intensity focused ultrasound ablation, and systemic anticancer therapy. In patients with minimal symptoms and progression, active surveillance without specific treatment may be considered. Systemic treatment should be considered for patients with multiple progressive lesions by RECIST criteria. Furthermore, testing for cancer gene mutations, including BRAF, NTRK, and RET genes, is recommended for personalized therapy. Systemic therapy should be decided based on shared decision-making between the patient and specialist, considering anticipated benefits and risks. Regular assessment of treatment responses and evaluation of adverse events is essential, with dose adjustment based on these assessments. The optimal time of use, clinical approaches for the prevention and control of adverse events, and individualized treatment approaches based on patient characteristics will be of great help in the treatment of patients with RAI-refractory DTC.

Abstract

The primary treatment for differentiated thyroid cancer (DTC) with distant metastasis is high-dose radioactive iodine (RAI) therapy, which can have various effects depending on the iodine uptake of thyroid cancer cells. The iodine uptake of metastatic lesions decreases over time, and approximately 40-70% of patients eventually develop RAI refractory disease. Although the prognosis of patients with RAI refractory DTC is very poor, clinical outcomes vary depending on the location and progression of metastatic lesions. Therefore, it is crucial to determine which patients should receive active systemic therapy with tyrosine kinase inhibitor (TKI) and how to apply local treatment before or during systemic therapy. This guideline covers the definition, treatment principles, systemic anticancer agents, and complications of progressive RAI-refractory DTC. RAI refractory DTC is defined as (1) the absence of RAI uptake on whole body scan, (2) presence of RAI uptake in some lesions but not in others, or (3) disease progression despite RAI uptake. Treatment options for RAI refractory DTC include surgery, external beam radiation therapy, locoregional therapies such as high-intensity focused ultrasound ablation, and systemic anticancer therapy. In patients with minimal symptoms and progression, active surveillance without specific treatment may be considered. Systemic treatment should be considered for patients with multiple progressive lesions by RECIST criteria. Furthermore, testing for cancer gene mutations, including BRAF, NTRK, and RET genes, is recommended for personalized therapy. Systemic therapy should be decided based on shared decision-making between the patient and specialist, considering anticipated benefits and risks. Regular assessment of treatment responses and evaluation of adverse events is essential, with dose adjustment based on these assessments. The optimal time of use, clinical approaches for the prevention and control of adverse events, and individualized treatment approaches based on patient characteristics will be of great help in the treatment of patients with RAI-refractory DTC.

참고문헌 (45)

  1. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
  2. Cho SW, "Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors", Thyroid, 24(2), pp.277~286 (2014)
  3. Kim M, "Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung", Thyroid, 27(1), pp.49~58 (2017)
  4. Feine U, "Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer", J Nucl Med, 37(9), pp.1468~1472 (1996)
  5. Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
  6. Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
  7. Brose MS, "Cabozantinib for radioiodine-refractory differentiated thyroid cancer(COSMIC-311) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 22(8), pp.1126~1138 (2021)
  8. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
  9. Fugazzola L, "2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodinerefractory thyroid cancer", Eur Thyroid J, 8(5), pp.227~245 (2019)
  10. Tuttle RM, "Controversies, consensus, and collaboration in the use of(131)I therapy in differentiated thyroid cancer : a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association", Thyroid, 29(4), pp.461~470 (2019)
  11. Cabanillas ME, "Information for clinicians : approach to the patient with progressive radioiodinerefractory thyroid cancer-when to use systemic therapy", Thyroid, 27(8), pp.987~993 (2017)
  12. Van Nostrand D, "Radioiodine refractory differentiated thyroid cancer : time to update the classifications", Thyroid, 28(9), pp.1083~1093 (2018)
  13. Sabra MM, "Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cellderived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans", Thyroid, 22(9), pp.877~883 (2012)
  14. Leboulleux S, "Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels", Thyroid, 22(8), pp.832~838 (2012)
  15. Schwartz LH, "RECIST 1. 1-Standardisation and diseasespecific adaptations : perspectives from the RECIST Working Group", Eur J Cancer, 62, pp.138~145 (2016)
  16. Filetti S, "Thyroid cancer : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 30(12), pp.1856~1883 (2019)
  17. Aashiq M, "Radioiodine-refractory thyroid cancer : molecular basis of redifferentiation therapies, management, and novel therapies", Cancers(Basel), 11(9), pp.1382~ (2019)
  18. Shen X, "A six-genotype genetic prognostic model for papillary thyroid cancer", Endocr Relat Cancer, 24(1), pp.41~52 (2017)
  19. Ho AL, "Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer : a phase III, randomized, placebo-controlled trial(ASTRA)", J Clin Oncol, 40(17), pp.1870~1878 (2022)
  20. Rothenberg SM, "Redifferentiation of iodine-refractory BRAF V600Emutant metastatic papillary thyroid cancer with dabrafenib", Clin Cancer Res, 21(5), pp.1028~1035 (2015)
  21. Leboulleux S, "A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p. V600E-mutated differentiated thyroid cancer", Clin Cancer Res, 29(13), pp.2401~2409 (2023)
  22. Lee YA, "NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake", J Clin Invest, 131(18), pp.e144847~ (2021)
  23. Ho AL, "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer", N Engl J Med, 368(7), pp.623~632 (2013)
  24. Filetti S, "ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer", Ann Oncol, 33(7), pp.674~684 (2022)
  25. "NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Thyroid carcinoma. version 1" (2024)[URL]
  26. Zheng X, "A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer", Clin Cancer Res, 27(20), pp.5502~5509 (2021)
  27. Cancer Genome Atlas Research Network, "Integrated genomic characterization of papillary thyroid carcinoma", Cell, 159(3), pp.676~690 (2014)
  28. Drilon A, "Targeting RET-driven cancers : lessons from evolving preclinical and clinical landscapes", Nat Rev Clin Oncol, 15(3), pp.151~167 (2018)
  29. Subbiah V, "Advances in targeting RET-dependent cancers", Cancer Discov, 10(4), pp.498~505 (2020)
  30. Hechtman JF, "NTRK insights : best practices for pathologists", Mod Pathol, 35(3), pp.298~305 (2022)
  31. Yakushina VD, "Gene fusions in thyroid cancer", Thyroid, 28(2), pp.158~167 (2018)
  32. Lee SE, "Interlaboratory comparison study(ring test)of next-generation sequencing-based NTRK fusion detection in South Korea", Cancer Res Treat, 55(1), pp.28~40 (2023)
  33. Salvatore D, "The importance of the RET gene in thyroid cancer and therapeutic implications", Nat Rev Endocrinol, 17(5), pp.296~306 (2021)
  34. Wirth LJ, "Efficacy of Selpercatinib in RET-altered thyroid cancers", N Engl J Med, 383(9), pp.825~835 (2020)
  35. Subbiah V, "Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer(ARROW) : a multi-cohort, open-label, registrational, phase 1", 2 study, 2021, pp.9(8), 491~501
  36. Subbiah V, "Pralsetinib in patients with advanced", metastatic rearranged during transfection(RET)-altered thyroid cancer : updated efficacy and safety data from the ARROW Study, 2024, pp.34(1), 26~40
  37. Laetsch TW, "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions : phase 1 results from a multicentre, open-label, phase 1", 2 study, 2018, pp.19(5), 705~714
  38. Waguespack SG, "Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma", Eur J Endocrinol, 186(6), pp.631~643 (2022)
  39. Drilon A, "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children", N Engl J Med, 378(8), pp.731~739 (2018)
  40. Demetri GD, "Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors", Clin Cancer Res, 28(7), pp.1302~1312 (2022)
  41. Busaidy NL, "Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer : results of a randomized, phase 2, open-label multicenter trial", Thyroid, 32(10), pp.1184~1192 (2022)
  42. Chrisoulidou A, "Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer", Onco Targets Ther, 8, pp.2435~2442 (2015)
  43. Blevins DP, "Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer", Thyroid, 24(5), pp.918~922 (2014)
  44. Kim M, "Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma : real-world outcomes in a multicenter retrospective cohort study", Thyroid, 33(1), pp.91~99 (2023)
  45. Jeon Y, "Combination of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer", Cancer Res Treat (2024)

관련 논문AI추천

대한갑상선학회 갑상선분화암 진료권고안; Part III. 진행성 갑상선분화암의 치료 - 제1-2장 갑상선 수술부위 재발 또는 경부 전이림프절에 대한 수술 및 비수술적 치료 2024강호철, 구본석, 권형주, 김선욱, 김원웅, 김정한, 나동규, 박영주, 박준욱, 백교림, 송영신, 우승훈, 원호륜, 유창환, 이민경, 이은경, 이준협, 이지예, 이초록, 임동준, 임재열, 정윤재대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호대한갑상선학회 갑상선분화암 진료권고안; Part III. 진행성 갑상선분화암의 치료 - 제5장 진행성 갑상선분화암 전이 병소의 부위별 치료 원칙 2024강호철, 김선욱, 김원구, 나동규, 박영주, 서영덕, 송영신, 신동엽, 이상우, 이은경, 임동준, 정경연, 정윤재대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제7장 갑상선분화암에서 수술 후 추가적인 외부 방사선조사나 항암 치료의 역할 2024강호철, 김선욱, 김원구, 나동규, 문신제, 박영주, 송영신, 신동엽, 이은경, 임동준, 정윤재대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호대한갑상선학회 갑상선분화암 진료권고안; Part III. 진행성 갑상선분화암의 치료 - 제3장 진행성 갑상선분화암 환자의 방사성요오드 치료 2024강호철, 김근영, 김선욱, 나동규, 박소현, 박영주, 방지인, 서영덕, 송영신, 오소원, 이상우, 이은경, 임동준, 정아리, 정윤재, 홍채문대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호방사성 옥소치료에 내성을 가진 분화 갑상선암의 진단 및 치료적 접근류준선대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2012 · 제55권 제7호방사성요오드 불응성 분화갑상선암의 치료, 현재의상황과 향후 전망송영기대한갑상선학회 · International Journal of Thyroidology2021 · 제14권 제2호

이 간행물의 다른 논문 (16건)

대한갑상선학회 갑상선분화암 진료권고안; 개요 및 요약 2024조윤영, 이승은, 박소현, 이상우, 이준협, 이지예, 이지은, 김희경, 이은경, 이민경, 김미진, 김선욱, 김정한, 정경연, 강호철, 임동준, 서영덕, 김원구, 이시훈, 문정은, 신수진, 김원배, 윤지희, 오소원, 송영신, 이가희, 임재열, 전윤경, 신동엽, 정윤재, 나동규, 김근영, 이영아, 김보현, 방지인, 조관훈, 박영주, 홍채문, 문신제, 홍아람, 백교림, 정웅윤, 정아리, 원호륜, 권형주, 나희영, 이초록, 우승훈, 박도준, 유창환, 정찬권, 박준욱, 김원웅, 구본석, 안화영pp. 1-20대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제1장 갑상선분화암의 수술 전 병기를 예측하기 위한 영상 및 혈액 검사 2024김선욱, 이민경, 박영주, 이은경, 이상우, 나동규, 정윤재, 송영신, 임동준, 강호철, 이지예, 조관훈, 방지인pp. 21-29대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제2장 갑상선분화암의 적절한 초기 수술 2024조윤영, 김정한, 김선욱, 이민경, 박영주, 이은경, 김희경, 이지예, 이준협, 나동규, 정윤재, 임재열, 송영신, 윤지희, 임동준, 강호철, 구본석, 김원웅, 박준욱, 정찬권, 유창환, 우승훈, 이초록, 권형주, 원호륜, 백교림pp. 30-52대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제3장 갑상선분화암의 수술 전후 합병증 평가 2024김선욱, 박영주, 이시훈, 유창환, 홍아람, 원호륜, 우승훈, 박준욱, 구본석, 강호철, 임동준, 이은경, 나동규, 정윤재, 전윤경, 임재열, 송영신pp. 53-60대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제4장 갑상선분화암의 수술 후 병리학적 진단 및 병기 결정 2024김선욱, 신수진, 나희영, 정찬권, 강호철, 임동준, 송영신, 정윤재, 나동규, 이은경, 박영주pp. 61-67
원문 보기